Chemotherapy for metastatic melanoma

References

• Jemal A, Devesa SS, Hartge P et al. Recent trends in cutaneous melanoma incidence among whites in the United States. J. Natl Cancer Inst. 93, 678–683 (2001).
   PubMed Web of Science ®Google Scholar
• Florez A, Cruces M. Melanoma epidemic: true or false? Int. J. Dermatol. 43(6), 405–407 (2004).
   PubMed Web of Science ®Google Scholar
• Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. Br. Med. J. 331(7515), 481 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1), 3–27 (2004).
   PubMed Web of Science ®Google Scholar
• Buzaid AC, Anderson CM. The changing prognosis of melanoma. Curr. Oncol. Rep. 2(4), 322–328 (2000).
   PubMedGoogle Scholar
• Anderson CM, Buzaid AC, Legha SS et al. Systemic treatments for advanced cutaneous melanoma. Oncology 9(11), 1149–1158 (1995).
   PubMedGoogle Scholar
• Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer 40(12), 1825–1836 (2004).
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Newlands ES, Lee SM et al. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 13(4), 910–913 (1995).
   PubMed Web of Science ®Google Scholar
• Chang A, Hunt M, Parkinson DR et al. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Co-operative Oncology Group. Am. J. Clin. Oncol. 16(2), 152–155 (1993).
   PubMed Web of Science ®Google Scholar
• Nelimark RA, Peterson BA, Vosika GJ et al. Vindesine for metastatic malignant melanoma. A Phase II trial. Am. J. Clin. Oncol. 6(5), 561–564 (1983).
   PubMed Web of Science ®Google Scholar
• Nathan FE, Mastrangelo MJ. Systemic therapy in melanoma. Semin. Surg. Oncol. 14(4), 319–327 (1998).
   PubMed Web of Science ®Google Scholar
• Falkson CI, Falkson G, Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest. New Drugs 12(3), 251–254 (1994).
   PubMed Web of Science ®Google Scholar
• Legha SS, Ring S, Papadopoulos N et al. A Phase II trial of taxol in metastatic melanoma. Cancer 65(11), 2478–2481 (1990).
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Weiss GR, Legha SS et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J. Clin. Oncol. 13(12), 2895–2899 (1995).
   PubMed Web of Science ®Google Scholar
• Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J. Clin. Oncol. 22(6), 1118–1125 (2004).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18(1), 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Luikart SD, Kennealey GT, Kirkwood JM. Randomized Phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J. Clin. Oncol. 2(3), 164–168 (1984).
   PubMed Web of Science ®Google Scholar
• Lopez M, Perno CF, Di Lauro L et al. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Invest. New Drugs 2(3), 319–322 (1984).
   Google Scholar
• Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 17(9), 2745–2751 (1999).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 21(17), 3351–3356 (2003).
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Lis E, Menell JH et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a Phase II study. Cancer 103(12), 2590–2597 (2005).
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Tsoutsos D, Kalofonos H et al. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized Phase II study of the Hellenic Co-operative Oncology Group. Ann. Oncol. 6(6), 950–957 (2005).
   Google Scholar
• Mornex F, Thomas L, Mohr P et al. A prospective randomized multicentre Phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 13(1), 97–103 (2003).
   PubMed Web of Science ®Google Scholar
• Lotze MT, Dallal RM, Kirkwood JM et al. Cutaneous melanoma. In: Cancer: Principles & Practice of Oncology. 6th ed. Lippincott, Williams & Wilkins, PA, USA, 2012–2069 (2001).
   Google Scholar
• Jungnelius U, Rinborg U, Aamdal S et al. Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised Phase III trial. Eur. J. Cancer. 34(9), 1368–1374 (1998).
   PubMed Web of Science ®Google Scholar
• Jelic S, Babovic N, Kovcin V et al. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. Melanoma Res. 12(1), 91–98 (2002).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Ferri W, Gooding W et al. A Phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 85(9), 1979–1984 (1999).
   PubMed Web of Science ®Google Scholar
• Wittes RE, Wittes JT, Golbey RB. Combination chemotherapy in metastatic malignant melanoma: a randomized study of three DTIC-containing combination. Cancer 41(2), 415–421 (1978).
   PubMed Web of Science ®Google Scholar
• McKelvey EM, Luce JK, Vaitkevicius VK et al. Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. Cancer 39(1), 5–10 (1977).
   PubMed Web of Science ®Google Scholar
• Eigentler T, Caroli U, Radny P et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomized clinical trials. Lancet Oncol. 4(12), 748–59 (2003).
   PubMed Web of Science ®Google Scholar
• Del Prete SA, Maurer LH, O’Donnel J et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 68(11), 1403–1405 (1984).
   PubMedGoogle Scholar
• Legha SS, Ring S, Papadopoulos N et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64(10), 2024–2029 (1989).
   PubMed Web of Science ®Google Scholar
• Chiarion-Sileni V, Nortilli R, Aversa SM et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res. 11(2), 189–196 (2001).
   PubMed Web of Science ®Google Scholar
• Creagan ET, Suman VJ, Dalton RJ et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J. Clin. Oncol. 17(6), 1884–1990 (1999).
   PubMed Web of Science ®Google Scholar
• Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 14(7), 2083–2090 (1996).
   PubMed Web of Science ®Google Scholar
• Johnston SR, Constenla DO, Moore J et al. Randomized Phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon α (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma. Br. J. Cancer 77(8), 1280–1286 (1998).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Lorigan P, Owen J et al. A randomized Phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br. J. Cancer 82(6), 1158–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Buzaid AC, Legha SS, Winn R et al. Cisplatin (C), vinblastine (V), dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results Phase III cancer community Oncology program (CCOP). Proceedings of the 29th American Society of Clinical Oncology. FL, USA, 1328 abstract (1993).
   Google Scholar
• Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol. 20(8), 2045–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Rumke P, Kleeberg UR, MacKie RM et al. Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A Phase II study of the EORTC Malignant Melanoma Co-operative Group. Melanoma Res. 2(3), 153–156 (1992).
   PubMed Web of Science ®Google Scholar
• Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N. Engl. J. Med. 327(8), 516–523 (1992).
   PubMed Web of Science ®Google Scholar
• McClay EF, Jones JA, Winski PJ et al. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin. Cancer Res. 56(17), 3993–3997 (1996).
   PubMed Web of Science ®Google Scholar
• McClay EF, Mastrangelo MJ, Berd D et al. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int. J. Cancer. 50(4), 553–556 (1992).
   PubMed Web of Science ®Google Scholar
• Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Co-operative Oncology Group study. J. Clin. Oncol. 16(5), 1743–1751 (1998).
   PubMed Web of Science ®Google Scholar
• Lens MB, Remain T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Cancer 98(7), 1355–1361 (2003).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7–17 (1996).
   PubMed Web of Science ®Google Scholar
• Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon α-2a in the treatment of advanced melanoma. J. Clin. Oncol. 12(4), 806–811 (1994).
   PubMed Web of Science ®Google Scholar
• Thomson DB, Adena M, McLeod GR et al. Interferon-α 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. 3(2), 133–138 (1993).
   PubMed Web of Science ®Google Scholar
• Young AM, Marsden J, Goodman A et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-α (IFN-α) in metastatic melanoma. Clin. Oncol. (R. Coll. Radiol.) 13(6), 458–465 (2001).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. 11(1), 75–81 (2001).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Stoter G, Punt J et al. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Co-operative Group. Cancer J. Sci. Am. 3(S1), S22–S28 (1997).
   Google Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271(12), 907–913 (1994).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Fisher RI, Sunderland M et al. Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon α-2a in patients with advanced melanoma. J. Clin. Oncol. 11(10), 1969–1977 (1993).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Conradt C, Legha SS et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J. Clin. Oncol. 16, 2921–2929 (1998).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lee S, Flaherty LE et al. A prospective randomized Phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-co-ordinated intergroup trial. Proceedings of the 39th American Society of Clinical Oncology. IL, USA, 2847 abstract (2003).
   Google Scholar
• Keilholz U, Goey SH, Punt CJ et al. Interferon α-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Co-operative Group. J. Clin. Oncol. 15, 2579–2588 (1997).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin and IFNa-2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized Phase III trial 18951. Proceedings of the 39th American Society of Clinical Oncology. IL, USA, 2848 abstract (2003).
   Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon α-2b. J. Clin. Oncol. 17, 968–975 (1999).
   PubMed Web of Science ®Google Scholar
• Tsao H, Atkins MB and Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med. 351(10), 998–1012 (2004).
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Dalerba P et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94(11), 805–818 (2002).
   PubMed Web of Science ®Google Scholar
• Kao JY, Zhang M, Chen CM et al. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol. Lett. 101(2), 154-159 (2005).
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Nestle FO, Broecker EB et al. Dacarbacine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized Phase III study. Proceedings of the 40th American Society of Clinical Oncology. LA, USA, 7508 abstract (2004).
   Google Scholar
• Millward MJ, Bedikian AY, Conry RM et al. Randomized multinational Phase III trial of dacarbazine with or without bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma: analysis of long-term survival. Proceedings of the 40th American Society of Clinical Oncology. LA, USA, 7505 abstract (2004).
   Google Scholar
• Folkman J. Angiogenesis-dependent diseases. Semin. Oncol. 28, 536–542 (2001).
   PubMed Web of Science ®Google Scholar
• Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res. 14(1), 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Danson Lorigan, Arance et al. Randomized Phase II study of temozolomide given every 8 h or daily with either interferon α-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol. 21(13), 2551–2557 (2003).
   PubMed Web of Science ®Google Scholar
• Carson WE, Biber J, Shah N et al. A Phase II trial of a recombinant humanized monoclonal antivascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma. Proceedings of the 39th American Society of Clinical Oncology. IL, USA, 2873 abstract (2003).
   Google Scholar
• Gorden A, Osman I, Gai W et al. Analysis of BRAF and N-RAS mutations in metastatic -melanoma tissues. Cancer Res. 63, 3955–3957 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmad T, Marais R, Pyle L et al. BAY 43–9006 in patients with advanced melanoma: the Royal Marsden experience. Proceedings of the 40th American Society of Clinical Oncology. LA, USA, 7506 abstract (2004).
   Google Scholar
• Flaherty K, Brose MS, Schuchter L et al. Phase I/II trial of BAY 43–9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proceedings of the 40th American Society of Clinical Oncology. LA, USA, 7507 (2004).
   Google Scholar
• Atzpodien J, Neuber K, Kamanabrou D et al. Combination chemotherapy with or without sc. IL-2 and IFN-α: results of a prospectively randomized trial of the Co-operative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer 86(2), 179–84, (2002).
   PubMed Web of Science ®Google Scholar
• Hauschild A, Garbe C, Stolz W et al. Dacarbazine and interferon α with or without interleukin-2 in metastatic melanoma: a randomized Phase III multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Br. J. Cancer 84(8), 1036–1042 (2001).
   PubMed Web of Science ®Google Scholar
• Ridolfi R, Chiaron-Sileni V, Guida M et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon α-2b in advanced melanoma out-patients: results from an Italian multicenter Phase III randomized clinical trial. J. Clin. Oncol. 20(6), 1600–1607 (2002).
   PubMed Web of Science ®Google Scholar
• Dorval T, Negrier S, Chevreasu C et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-α-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 85(5), 1060–1066 (1999).
   PubMed Web of Science ®Google Scholar